• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.异二价配体结合的“部分”竞争可能会被误认为是变构相互作用:不同靶点相互作用模型的比较
Br J Pharmacol. 2015 May;172(9):2300-15. doi: 10.1111/bph.13053. Epub 2015 Mar 17.
2
Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods.使用放射性配体结合和药理学无效方法估算变构配体的亲和力。
Mol Pharmacol. 1988 Feb;33(2):187-94.
3
Elucidation of direct competition and allosteric modulation of small-molecular-weight protein ligands using surface plasmon resonance methods.利用表面等离子体共振方法阐明小分子蛋白质配体的直接竞争和变构调节
J Mol Recognit. 2015 Aug;28(8):480-91. doi: 10.1002/jmr.2465. Epub 2015 Mar 12.
4
Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.探索亲和力:理解二价和异二价配体在功能亲和力和靶点驻留时间方面的潜在优势。
Br J Pharmacol. 2013 Apr;168(8):1771-85. doi: 10.1111/bph.12106.
5
Cooperativity between the orthosteric and allosteric ligand binding sites of RORγt.RORγt 的变构配体结合位点与正位配体结合位点之间的协同作用。
Proc Natl Acad Sci U S A. 2021 Feb 9;118(6). doi: 10.1073/pnas.2021287118.
6
Analysis of equilibrium binding of an orthosteric tracer and two allosteric modulators.分析正构位示踪剂与两种变构调节剂的平衡结合。
PLoS One. 2019 Mar 27;14(3):e0214255. doi: 10.1371/journal.pone.0214255. eCollection 2019.
7
Large-Scale Screening of Per- and Polyfluoroalkyl Substance Binding Interactions and Their Mixtures with Nuclear Receptors.全氟和多氟烷基物质结合相互作用及其与核受体混合物的大规模筛选。
Int J Mol Sci. 2024 Jul 28;25(15):8241. doi: 10.3390/ijms25158241.
8
Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor.G蛋白偶联受体变构调节的分子机制:来自人A1腺苷受体结合动力学研究的见解
Br J Pharmacol. 2014 Dec;171(23):5295-312. doi: 10.1111/bph.12836. Epub 2014 Sep 5.
9
Allosteric small molecule modulators of nuclear receptors.核受体的变构小分子调节剂。
Mol Cell Endocrinol. 2019 Apr 5;485:20-34. doi: 10.1016/j.mce.2019.01.022. Epub 2019 Jan 28.
10
GPCR drug discovery through the exploitation of allosteric drug binding sites.通过利用变构药物结合位点进行GPCR药物发现。
Recept Channels. 2002;8(5-6):261-8.

引用本文的文献

1
Divalent ligand-monovalent molecule binding.二价配体-单价分子结合
Soft Matter. 2021 Jun 2;17(21):5375-5383. doi: 10.1039/d1sm00070e.
2
G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.哮喘治疗中的 G 蛋白偶联受体:药理学和药物作用。
Pharmacol Rev. 2020 Jan;72(1):1-49. doi: 10.1124/pr.118.016899.
3
Bitopic fluorescent antagonists of the A adenosine receptor based on pyrazolo[4,3-][1,2,4]triazolo[1,5-]pyrimidin-5-amine functionalized congeners.基于吡唑并[4,3-][1,2,4]三唑并[1,5-]嘧啶-5-胺官能化同系物的 A 型腺苷受体的双位荧光拮抗剂。
Medchemcomm. 2017 Aug 1;8(8):1659-1667. doi: 10.1039/C7MD00247E. Epub 2017 Jun 22.
4
Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugs.双价和诱导契合样结合药物在体内的独特靶位占有率。
Br J Pharmacol. 2017 Dec;174(23):4233-4246. doi: 10.1111/bph.13989. Epub 2017 Oct 18.
5
What Do Structures Tell Us About Chemokine Receptor Function and Antagonism?结构能告诉我们关于趋化因子受体功能及拮抗作用的哪些信息?
Annu Rev Biophys. 2017 May 22;46:175-198. doi: 10.1146/annurev-biophys-051013-022942.
6
On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.关于药物与细胞靶点的双态“诱导契合”结合的不同实验表现。
Br J Pharmacol. 2016 Apr;173(8):1268-85. doi: 10.1111/bph.13445. Epub 2016 Mar 15.

本文引用的文献

1
Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors.生物系统中的多价相互作用:对多价配体和抑制剂设计与应用的启示
Angew Chem Int Ed Engl. 1998 Nov 2;37(20):2754-2794. doi: 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3.
2
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.《2013/14药理学简明指南:G蛋白偶联受体》
Br J Pharmacol. 2013 Dec;170(8):1459-581. doi: 10.1111/bph.12445.
3
Activation and allosteric modulation of a muscarinic acetylcholine receptor.毒蕈碱型乙酰胆碱受体的激活和变构调节。
Nature. 2013 Dec 5;504(7478):101-6. doi: 10.1038/nature12735. Epub 2013 Nov 20.
4
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands.国际药理学联合会/英国药理学学会药物靶点和配体百科全书:一个由专家驱动的药物靶点和配体知识库。
Nucleic Acids Res. 2014 Jan;42(Database issue):D1098-106. doi: 10.1093/nar/gkt1143. Epub 2013 Nov 14.
5
Hybrid bombesin analogues: combining an agonist and an antagonist in defined distances for optimized tumor targeting.混合蛙皮素类似物:在特定距离内结合激动剂和拮抗剂,以优化肿瘤靶向。
J Am Chem Soc. 2013 Nov 13;135(45):16793-6. doi: 10.1021/ja4087648. Epub 2013 Oct 31.
6
Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors.基于结构的配体发现,针对多巴胺受体的正构和变构口袋。
Mol Pharmacol. 2013 Dec;84(6):794-807. doi: 10.1124/mol.113.088054. Epub 2013 Sep 10.
7
Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.用于异价配体结合的简化模型:在何种情况下适用,以及哪些因素会影响其靶标停留时间。
Naunyn Schmiedebergs Arch Pharmacol. 2013 Nov;386(11):949-62. doi: 10.1007/s00210-013-0881-0. Epub 2013 Jun 28.
8
Application of receptor theory to allosteric modulation of receptors.受体理论在别构调节受体中的应用。
Prog Mol Biol Transl Sci. 2013;115:217-90. doi: 10.1016/B978-0-12-394587-7.00006-3.
9
Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.探索亲和力:理解二价和异二价配体在功能亲和力和靶点驻留时间方面的潜在优势。
Br J Pharmacol. 2013 Apr;168(8):1771-85. doi: 10.1111/bph.12106.
10
Bridging the gap: bitopic ligands of G-protein-coupled receptors.弥合差距:G 蛋白偶联受体的双配体。
Trends Pharmacol Sci. 2013 Jan;34(1):59-66. doi: 10.1016/j.tips.2012.10.003. Epub 2012 Nov 20.

异二价配体结合的“部分”竞争可能会被误认为是变构相互作用:不同靶点相互作用模型的比较

'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.

作者信息

Vauquelin Georges, Hall David, Charlton Steven J

机构信息

Department Molecular and Biochemical Pharmacology, Vrije Universiteit Brussel, Brussels, Belgium.

出版信息

Br J Pharmacol. 2015 May;172(9):2300-15. doi: 10.1111/bph.13053. Epub 2015 Mar 17.

DOI:10.1111/bph.13053
PMID:25537684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4403095/
Abstract

BACKGROUND AND PURPOSE

Non-competitive drugs that confer allosteric modulation of orthosteric ligand binding are of increasing interest as therapeutic agents. Sought-after advantages include a ceiling level to drug effect and greater receptor-subtype selectivity. It is thus important to determine the mode of interaction of newly identified receptor ligands early in the drug discovery process and binding studies with labelled orthosteric ligands constitute a traditional approach for this. According to the general allosteric ternary complex model, allosteric ligands that exhibit negative cooperativity may generate distinctive 'competition' curves: they will not reach baseline levels and their nadir will increase in par with the orthosteric ligand concentration. This behaviour is often considered a key hallmark of allosteric interactions.

EXPERIMENTAL APPROACH

The present study is based on differential equation-based simulations.

KEY RESULTS

The differential equation-based simulations revealed that the same 'competition binding' pattern was also obtained when a monovalent ligand binds to one of the target sites of a heterobivalent ligand, even if this process is exempt of allosteric interactions. This pattern was not strictly reciprocal when the binding of each of the ligands was recorded. The prominence of this phenomenon may vary from one heterobivalent ligand to another and we suggest that this phenomenon may take place with ligands that have been proposed to bind according to 'two-domain' and 'charnière' models.

CONCLUSIONS AND IMPLICATIONS

The present findings indicate a familiar experimental situation where bivalency may give rise to observations that could inadvertently be interpreted as allosteric binding. Yet, both mechanisms could be differentiated based on alternative experiments and structural considerations.

摘要

背景与目的

作为治疗药物,能够对正构配体结合进行变构调节的非竞争性药物越来越受到关注。其备受追捧的优势包括药物效应的上限水平以及更高的受体亚型选择性。因此,在药物研发过程的早期确定新发现的受体配体的相互作用模式非常重要,而使用标记的正构配体进行结合研究是实现这一目标的传统方法。根据一般的变构三元复合物模型,表现出负协同性的变构配体可能会产生独特的“竞争”曲线:它们不会达到基线水平,且其最低点会随着正构配体浓度的增加而升高。这种行为通常被认为是变构相互作用的关键标志。

实验方法

本研究基于基于微分方程的模拟。

关键结果

基于微分方程的模拟显示,当单价配体与异二价配体的一个靶位点结合时,即使该过程不存在变构相互作用,也会获得相同的“竞争结合”模式。当记录每个配体的结合情况时,这种模式并非严格可逆。这种现象的显著程度在不同的异二价配体之间可能会有所不同,我们认为这种现象可能会发生在那些根据“双结构域”和“铰链”模型被认为能够结合的配体上。

结论与启示

本研究结果表明,在常见的实验情况下,二价性可能会导致一些观察结果被不经意地解释为变构结合。然而,这两种机制可以通过其他实验和结构方面的考虑加以区分。